Research and Development plays a key role in Polichem’s international activities and the company organisation. Because of this, a significant percentage of the annual turnover is re-invested in this area. We stand committed to developing and delivering innovative medicines and medical devices that respond to specific medical needs.
|P-3058||Onychomycosis||Pivotal Phase III and paediatric studies in EU
Pivotal Phase III and Paediatric study plan agreed with FDA
|P-3073||Nail Psoriasis||Pivotal Phase III in EU and Paediatric study plan agreed with EMA
FDA IND opened
|P-3074||AGA (androgenetic alopecia)||Pivotal Phase III in EU|
|P-3085||Psoriasis||Phase II in EU|
Please have a look at our publications.